Neogen (NASDAQ: NEOG) Earnings Preview: FDA Warning Casts Shadow on Animal Health Stock

• Neogen (NASDAQ: NEOG) is expected to report fiscal first-quarter earnings on October 6, 2026, although reports differ on the exact release timing.
• Analysts expect adjusted EPS of about $0.05, while revenue is projected to be roughly flat to slightly lower year over year.
• An FDA warning letter tied to Neogen Vet HYCOAT, a product linked to serious infections and at least 20 reported horse deaths, adds regulatory risk for animal health investors.

Neogen (NASDAQ: NEOG) makes products that help food safety and animal health businesses test for safety risks. The company is expected to report earnings on October 6, 2026. The timing is not fully clear, as some earnings calendars show the report before the market opens, while other reports point to after the market closes.

Wall Street estimates Neogen earnings of about $0.05 per share and revenue of approximately $208 million. A forecast highlighted by Zacks puts earnings at $0.05 per share, up 25% from a year earlier, and revenue at $208.09 million, down 0.5%. The earnings estimate has not changed over the past 30 days.

The report follows an FDA warning letter concerning Neogen Vet HYCOAT, a hyaluronate sodium sterile solution. The FDA linked contamination in the product to serious infections in nearly 100 horses and at least 20 reported horse deaths. Investigators reviewed more than 95 clinical cases, and FDA testing found viable fungal contamination in one product lot. The warning adds a regulatory issue for investors to weigh alongside Neogen’s earnings results.

Neogen’s earnings remain negative on a trailing basis, which makes its price-to-earnings ratio less useful for comparison with profitable companies. Its debt-to-equity ratio is around 0.38, which compares debt with shareholders’ equity. Its current ratio is 3.82, meaning current assets are 3.82 times current liabilities, a measure of the company’s ability to cover near-term bills.